Literature DB >> 31657842

The Clinical Trials Portfolio for On-label and Off-label Studies of Eculizumab.

Myung S Kim1, Vinay Prasad1,2,3.   

Abstract

Mesh：

Substances：

Year:  2020        PMID： 31657842      PMCID： PMC6820044          DOI： 10.1001/jamainternmed.2019.4694

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN： 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  5 in total

1.  Off-label use of the expensive orphan drug eculizumab in France 2009-2013 and the impact of literature: focus on the transplantation field.

Authors:  Johann Castañeda-Sanabria; David Hajage; Melisande Le Jouan; Anne Perozziello; Florence Tubach
Journal:  Eur J Clin Pharmacol       Date:  2016-02-26       Impact factor: 2.953

2.  Assessment of Pregabalin Postapproval Trials and the Suggestion of Efficacy for New Indications: A Systematic Review.

Authors:  Carole A Federico; Taiji Wang; Adélaïde Doussau; Jeffrey S Mogil; Dean Fergusson; Jonathan Kimmelman
Journal:  JAMA Intern Med       Date:  2019-01-01       Impact factor: 21.873

Review 3.  Epidemiology of rare anaemias in Europe.

Authors:  Beatrice Gulbis; Androulla Eleftheriou; Michael Angastiniotis; Sarah Ball; Jordi Surrallés; María Castella; Hermann Heimpel; Anita Hill; Joan-Lluis Vives Corrons
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

4.  The prevalence and cost of unapproved uses of top-selling orphan drugs.

Authors:  Aaron S Kesselheim; Jessica A Myers; Daniel H Solomon; Wolfgang C Winkelmayer; Raisa Levin; Jerry Avorn
Journal:  PLoS One       Date:  2012-02-21       Impact factor: 3.240

Review 5.  Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review.

Authors:  James Mattina; Benjamin Carlisle; Yasmina Hachem; Dean Fergusson; Jonathan Kimmelman
Journal:  PLoS Biol       Date:  2017-02-03       Impact factor: 8.029
  5 in total
  2 in total

Review 1.  Rituximab and eculizumab when treating nonmalignant hematologic disorders: infection risk, immunization recommendations, and antimicrobial prophylaxis needs.

Authors:  Elissa R Engel; Jolan E Walter
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

2.  The Inhibition of Complement System in Formal and Emerging Indications: Results from Parallel One-Stage Pairwise and Network Meta-Analyses of Clinical Trials and Real-Life Data Studies.

Authors:  Coralina Bernuy-Guevara; Hassib Chehade; Yannick D Muller; Julien Vionnet; François Cachat; Gabriella Guzzo; Carlos Ochoa-Sangrador; F Javier Álvarez; Daniel Teta; Débora Martín-García; Marcel Adler; Félix J de Paz; Frank Lizaraso-Soto; Manuel Pascual; Francisco Herrera-Gómez
Journal:  Biomedicines       Date:  2020-09-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.